智通财经APP获悉，截止9月10日收盘，东北电气(00042)、弘业期货(03678)、安德利果汁(02218)分列 AH溢价率前三位，溢价率分别为800.00%、227.63%、219.28%；宁德时代(03750)、恒瑞医药(01276)、 紫金矿业(02899)分列AH溢价率末三位，溢价率分别为-10.67%、-1.72%、4.00%。其中昭衍新药 (06127)、赣锋锂业(01772)、凯盛新能(01108)的偏离值位居前三，分别为25.76%、19.31%、18.78%；另 外，复星医药(02196)、龙源电力(00916)、龙蟠科技(02465)的偏离值位居后三，分别 为-21.97%、-20.23%、-17.81%。 前十大AH股溢价率排行 | 股票名称 | H股(港元) | A股 | 溢价率↓ | 偏离值 | | --- | --- | --- | --- | --- | | 东北电气(00042) | 0.300 | 2.25 | 800.00% | 15.86% | | 弘业期货(03678) | 4.270 | 11.68 | 227.63% | -8.94% | | 安德利果汁(022 ...

江蘇恒瑞醫藥股份有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 中國上海 2025年9月9日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 近日，江苏恒瑞医药股份有限公司（以下简称"公司"）子公司成都盛迪医 药有限 ...

Core Viewpoint - The article discusses the surge in A-share companies listing in Hong Kong through the A+H model, highlighting the significant increase in fundraising and the emergence of new listing methods, which reflect the growing interconnection between mainland and Hong Kong markets [3][4][5]. Group 1: A+H Listing Surge - In the first eight months of this year, Hong Kong Stock Exchange (HKEX) raised a total of HKD 134.5 billion in new stock financing, a nearly sixfold increase year-on-year [3]. - A+H listings accounted for 70% of the total fundraising in the first half of the year, indicating strong participation from A-share companies [3][4]. - Eleven A-share companies have successfully completed A+H listings this year, raising over HKD 90 billion, which represents about 70% of the total IPO fundraising in Hong Kong [4]. Group 2: New Listing Methods - New methods for A+H listings have emerged, such as share swap mergers and privatization, which provide companies with alternative financing channels [5]. - Zhejiang Hu-Hang-Zhou announced a share swap merger with Zhenyang Development to achieve A+H listing, while New Hope Group plans to privatize New Hope Energy through its wholly-owned subsidiary [5]. Group 3: Market Structure Improvement - The trend of A+H listings is expected to improve the industry structure of the Hong Kong market, attracting more capital and updating the composition of A+H listed companies [6]. - The recent strong performance of the Hong Kong stock market and the influx of southbound capital have led to a significant decrease in A+H premium, with some companies trading at a discount in A-shares compared to H-shares [6]. Group 4: A+H Premium Situation - As of September 5, among 161 A+H stocks, five had H-share prices exceeding A-share prices, with CATL showing the largest discount at -17.43% [7]. - The article notes that the A+H premium is expected to continue declining, influenced by the low interest rate environment in mainland China [7].

Group 1 - The Hong Kong Stock Exchange (HKEX) has seen a significant increase in new stock financing, reaching HKD 134.5 billion in the first eight months of the year, a nearly sixfold year-on-year growth, with A+H listings accounting for 70% of the total fundraising in the first half of the year [1][2] - A total of 11 A-share companies have completed A+H listings this year, raising over HKD 90 billion, which represents about 70% of the total IPO fundraising in the Hong Kong market [2] - More than 51 A-share companies are currently in the process of preparing for their listings in Hong Kong, including notable firms like SANY Heavy Industry and Sungrow Power Supply [2][3] Group 2 - Innovative listing methods are emerging in the current A+H expansion wave, such as share swap mergers and privatization, which provide companies with new financing channels and resource optimization opportunities [3] - Zhejiang Hu-Hang-Yong plans to achieve A+H listing through a share swap merger with Zhenyang Development, while New Hope Group intends to privatize New Hope Energy through its wholly-owned subsidiary and list on the Hong Kong Stock Exchange [3] Group 3 - The enthusiasm for A+H listings is driven by multiple factors, including support from mainland authorities for quality companies to list in Hong Kong and the ongoing optimization of the approval process by HKEX [4] - The trend of A+H listings is expected to improve the industry structure of the Hong Kong market, attracting more capital and updating the composition of A+H listed companies [5] Group 4 - As of September 5, 2023, among 161 A+H stocks, only 5 have H-share prices exceeding A-share prices, with CATL showing the largest discount at 17.43% [5][6] - The premium of A-shares over H-shares has significantly decreased, reflecting a shift in market sentiment and a revaluation of H-shares due to the low interest rate environment in mainland China [6]

Core Viewpoint - The A-share companies are increasingly enthusiastic about listing in Hong Kong, with a significant rise in A+H listings and innovative listing methods being adopted to enhance financing channels and optimize resource allocation [4][5][7][8]. Group 1: A+H Listing Trends - In the first eight months of this year, the total amount of new stock financing on the Hong Kong Stock Exchange reached HKD 134.5 billion, a year-on-year increase of nearly six times, with A+H listings accounting for 70% of the total fundraising in the first half of the year [4]. - A total of 11 A-share companies have completed A+H listings this year, raising over HKD 90 billion, which represents about 70% of the total IPO fundraising in Hong Kong [5]. - More than 51 A-share companies are currently in the process of preparing for listings in Hong Kong, indicating a strong interest in the A+H model [5]. Group 2: Innovative Listing Methods - New listing methods such as share swap mergers and privatization are emerging in the current A+H expansion wave, providing companies with new avenues for financing [7]. - Zhejiang Hu-Hang-Zhou announced a share swap merger with Zhenyang Development, aiming to achieve A+H listing through this innovative approach [7]. - New Hope Group plans to privatize its Hong Kong subsidiary, New Hope Energy, and list it in Hong Kong through an introduction listing, marking a unique method of achieving A+H status [7]. Group 3: Market Structure Improvement - The enthusiasm for A+H listings is driven by multiple factors, including support from the mainland for quality companies to list in Hong Kong and the optimization of the approval process by the Hong Kong Stock Exchange [8]. - The influx of quality companies from the A-share market is expected to improve the industry structure of the Hong Kong stock market, which has been characterized by a lack of diversity [8]. - As of September 5, among 161 A+H stocks, five had H-share prices exceeding A-share prices, with the largest discount being 17.43% for Ningde Times [8].

智通财经APP获悉，截止9月5日收盘，东北电气(00042)、弘业期货(03678)、安德利果汁(02218)分列AH 溢价率前三位，溢价率分别为831.03%、231.50%、231.11%；宁德时代(03750)、恒瑞医药(01276)、美 的集团(00300)分列AH溢价率末三位，溢价率分别为-9.90%、0.70%、5.55%。其中东北电气(00042)、中 芯国际(00981)、东江环保(00895)的偏离值位居前三，分别为51.67%、20.16%、19.58%；另外，龙蟠科 技(02465)、比亚迪股份(01211)、长城汽车(02333)的偏离值位居后三，分别 为-32.47%、-32.20%、-22.23%。 前十大AH股溢价率排行 股票名称 H股(港元) A股 溢价率↓ 偏离值 东北电气(00042) 0.290 2.25 831.03% 51.67% 弘业期货(03678) 4.190 11.6 231.50% -3.18% 安德利果汁(02218) 16.620 45.94 231.11% 8.10% 复旦张江(01349) 3.590 9.84 228.41% 11.86% 中石化油 ...

Core Viewpoint - Heng Rui Medicine has announced a new collaboration with Braveheart Bio for the global development and commercialization of its heart disease drug HRS-1893, marking its second NewCo transaction aimed at expanding its international presence [1][3]. Group 1: Transaction Details - Heng Rui Medicine will receive a total of $65 million in upfront payments, consisting of $32.5 million in cash and $32.5 million in equity from Braveheart Bio [1]. - After the technology transfer, Heng Rui will receive an additional $10 million milestone payment, along with potential milestone payments and sales royalties that could total up to $1.013 billion, bringing the maximum potential revenue from this deal to $1.088 billion [1]. - A joint management committee will be established to coordinate the global development and commercialization of the licensed product, with equal representation from both companies [1]. Group 2: Product Development Status - HRS-1893 is currently undergoing a Phase III clinical trial in China for obstructive hypertrophic cardiomyopathy, which is a common hereditary heart disease and a leading cause of sudden cardiac death among adolescents and athletes [2]. Group 3: Previous Transactions and Company Background - This is Heng Rui Medicine's second NewCo model transaction; the first involved licensing three GLP-1 innovative drugs to a newly established U.S. company, Kailera, for an upfront payment of $100 million and a potential total deal value of $6 billion [3]. - Braveheart Bio was established in 2024 in Delaware, USA, with major investors including Forbion Capital and OrbiMed, and is led by CEO Travis Murdoch, who has a history of successful clinical project management [3][4]. - As of September 5, Heng Rui Medicine's A-shares rose by 3.35%, with a market capitalization of 470.9 billion yuan, while its Hong Kong shares increased by 3.07%, with a market capitalization of 555.9 billion HKD [4].

Group 1 - The core viewpoint is that the innovative drug sector is experiencing a significant upward trend, with multiple companies showing substantial stock price increases ahead of the 2025 World Lung Cancer Conference [1] - Notable stock price increases include: 9.55% for 3SBio, 6.25% for Hengrui Medicine, and 5.16% for WuXi Biologics, indicating strong market interest [1] - The upcoming conference in Barcelona is expected to provide new development opportunities and market attention for innovative drug companies through the release of significant new products [1] Group 2 - In the first seven months of the year, China's innovative drug companies have seen a normalization in business development (BD) overseas, with license out amounts nearing $80 billion, a year-on-year increase of over 160% [2] - Analysts suggest that the essence of China's innovative drug overseas expansion is to replace certain ecological niches of foreign biotech companies, potentially leading to new breakthroughs in the global innovative drug industry [2] - The deep participation of Chinese innovative drugs in the global supply chain is expected to benefit significantly from the global innovation cycle [2]

责任编辑：栎树 恒瑞医药今早宣布，与美国BraveheartBio公司就其自主研发的心肌肌球蛋白（Myosin）小分子抑制剂 HRS-1893项目达成独家许可协议。据悉，该笔BD交易采取NewCo模式运作，恒瑞医药年内三笔BD交 易总金额已经突破150亿美元。根据协议条款，恒瑞医药将HRS-1893在除中国大陆、香港特别行政区、 澳门特别行政区及中国台湾地区以外的全球范围内开发、生产和商业化的独家权利有偿许可给 BraveheartBio。 恒瑞医药（01276）盘中涨超3%，截至发稿，股价上涨2.89%，现报83.70港元，成交额1.62亿港元。 ...

Group 1 - The core point of the article is that 恒瑞医药 has entered into an exclusive licensing agreement with BraveheartBio for its Myosin small molecule inhibitor HRS-1893, leading to a significant increase in its stock price [1] - 恒瑞医药's stock rose by 3.5% to HKD 84.2, with a trading volume of HKD 155 million [1] - The total amount of 恒瑞医药's three business development (BD) transactions this year has exceeded USD 15 billion [1] Group 2 - Under the agreement, 恒瑞医药 grants BraveheartBio exclusive rights to develop, produce, and commercialize HRS-1893 globally, excluding mainland China, Hong Kong, Macau, and Taiwan [1] - BraveheartBio will pay 恒瑞医药 an upfront payment of USD 65 million, which includes USD 32.5 million in cash and an equivalent of USD 32.5 million in BraveheartBio equity, along with a USD 10 million milestone payment after technology transfer [1] - Additionally, 恒瑞医药 could receive up to USD 1.013 billion in milestone payments related to clinical development and sales, as well as corresponding sales royalties [1]